Publication: Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria
Issued Date
2000-01-01
Resource Type
ISSN
00359203
Other identifier(s)
2-s2.0-0033784974
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Transactions of the Royal Society of Tropical Medicine and Hygiene. Vol.94, No.5 (2000), 545-548
Suggested Citation
M. Van Vugt, S. Looareesuwan, P. Wilairatana, R. McGready, L. Villegas, I. Gathmann, R. Mull, A. Brockman, N. J. White, F. Nosten Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene. Vol.94, No.5 (2000), 545-548. doi:10.1016/S0035-9203(00)90082-8 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/26015
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria
Abstract
The efficacy and safety of the 6-dose regimen of artemether-lumefantrine were assessed in an open randomized trial in children and adults presenting with acute, uncomplicated Plasmodium falciparum malaria in Thailand between November 1997 and March 1998. 200 patients were enrolled in 2 centres: 150 received artemether-lumefantrine (i.e., a median total dose of 9.6 mg/kg [interquartile range 8.7-10.7] and 57.9 mg/kg of lumefantrine [52.4-64.0]) and 50 the standard combination of artesunate (12 mg/kg over 3 d) and mefloquine (25 mg/kg). All patients had rapid initial clinical and parasitological responses. The 28 d cure rates were high: 97.7% (95% confidence interval [95% CI] 93.5-99.5%) for artemether-lumefantrine and 100% (95% CI 92.5-100%) for artesunate-mefloquine. The 6-dose regimen of artemether-lumefantrine was better tolerated than, and as effective as, artesunate-mefloquine, the current standard treatment in this area of multidrug-resistant P. falciparum malaria.